Sagimet Biosciences Inc. (Series A Common Stock, CUSIP 786700104) is the subject of an amended Schedule 13G filed by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen reporting ownership information as of June 30, 2025. The filing states that each reporting person beneficially owns 0 shares and 0% of the Series A common stock and reports no sole or shared voting or dispositive power. The filing includes the issuer address and identifies the filers and their Delaware organization or U.S. citizenship where applicable. The submission contains a certification that the shares were not acquired to influence control of the issuer.
Sagimet Biosciences, Inc. reported the entry into a material definitive agreement on August 14, 2025. The filing lists a Sales Agreement dated August 14, 2025 between Leerink Partners LLC and Sagimet Biosciences Inc., and includes an opinion from Goodwin Procter LLP and their consent. The document is an 8-K disclosing a material transaction; no financial terms, offering amounts, or other operational details are provided in the text supplied.
Sagimet Biosciences Inc. filed a prospectus supplement to offer up to $75.0 million of Series A common stock through an "at-the-market" sales agreement with Leerink Partners. The company’s Series A common stock trades on Nasdaq under the symbol SGMT and the last reported sale price referenced was $9.58 per share on August 13, 2025. Net proceeds are intended to advance development of denifanstat and other FASN inhibitors, for R&D, working capital and general corporate purposes.
The supplement highlights clinical progress: denifanstat met both primary and multiple secondary endpoints in a Phase 2b FASCINATE-2 MASH trial (statistically significant histologic and MRI-PDFF results) and received FDA Breakthrough Therapy designation for non-cirrhotic MASH F2-F3. Ascletis reported positive Phase 3 acne results for denifanstat in China. Sagimet is exploring Phase 3 funding and will initiate a Phase 1 PK study of denifanstat plus resmetirom in H2 2025, and started a Phase 1 trial of second candidate TVB-3567 in June 2025.
Woodline Partners LP disclosed beneficial ownership of 2,552,536 shares of Sagimet Biosciences Series A common stock, representing approximately 8.3% of the outstanding class. The shares are directly held by Woodline Master Fund LP, for which Woodline Partners serves as investment adviser, and the reporting page shows Woodline Partners has sole voting and dispositive power over these shares.
The filing was made on Schedule 13G and includes a certification that the securities were acquired and are held in the ordinary course of business and were not purchased to change or influence control of the issuer. The percentage is calculated using an aggregate share base of about 30,674,855 shares reported in the company’s quarterly report for the period ended March 31, 2025.
Sagimet Biosciences announced it has furnished a press release reporting its financial results for the quarter ended June 30, 2025 and has updated its investor slide presentation. The press release is furnished as Exhibit 99.1 and the slide deck as Exhibit 99.2.
Both exhibits are described in the report as being furnished rather than filed, and therefore are not deemed filed or incorporated by reference into other SEC filings except if expressly referenced. Company representatives will use the updated presentation in meetings with investors.
Sagimet Biosciences (SGMT) is a clinical-stage biopharmaceutical company developing FASN inhibitors led by denifanstat. The company reported strong clinical progress: its Phase 2b FASCINATE-2 trial in MASH achieved both primary endpoints with statistically significant histologic and biomarker improvements, and denifanstat received FDA Breakthrough Therapy designation for non-cirrhotic MASH with F2-F3 fibrosis. License partner Ascletis reported denifanstat met all primary and secondary endpoints in a Phase 3 acne trial and plans submission in China.
Financially, Sagimet had $135.5 million of cash, cash equivalents and marketable securities as of June 30, 2025 and expects these funds to support operations for at least 12 months. R&D spend rose sharply as programs advanced: six-month R&D expense was $22.59 million (up 95% year-over-year). Net loss for six months was $28.56 million, and the company had an accumulated deficit of $323.9 million. TVB-3567 received IND clearance in March 2025 and a first-in-human Phase 1 trial began in June 2025.
Sagimet Biosciences (SGMT) received an Amendment No. 1 to Schedule 13G from AP11 Limited and Ascletis Pharma Inc., dated 24 June 2025 and filed 29 June 2025. The filing reports beneficial ownership of 1,504,642 Series A common shares, equal to 4.9 % of the 30,674,855 shares outstanding as cited in Sagimet’s 10 June 2025 Form 8-K.
The reporting persons each claim sole voting and dispositive power over the entire position and report no shared power and no group status. Item 5 confirms “ownership of 5 percent or less,” meaning the investors are no longer 5 % holders under SEC rules. No additional transactions, control arrangements, or contingent rights are disclosed, and the document contains no risk factors, legal matters, or financial projections.
Overall, the amendment simply updates Sagimet’s ownership ledger, signalling that two related offshore entities now hold a sub-5 % passive stake without seeking influence over the issuer’s governance.